BiotechTube

Risankizumab + Comparator

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Conditions

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Trial Timeline

Jul 30, 2021 → Jun 1, 2032

NCT ID
NCT04846959

About Risankizumab + Comparator

Risankizumab + Comparator is a pre-clinical stage product being developed by AbbVie for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04846959. Target conditions include Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04846959Pre-clinicalRecruiting

Competing Products

20 competing products in Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
52
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85